Literature DB >> 8077059

Tumorigenicity of SV40 T antigen immortalized human prostate epithelial cells: association with decreased epidermal growth factor receptor (EGFR) expression.

V L Bae1, C K Jackson-Cook, A R Brothman, S J Maygarden, J L Ware.   

Abstract

Our primary objectives were to: 1) develop a system for the study of prostatic tumor evolution; and 2) examine the role of the epidermal growth factor/epidermal growth factor receptor (EGF/EGFR) pathway in prostate tumor progression. Adult human prostate epithelial cells previously immortalized by transfection with the SV40 T antigen gene (P69SV40T) produced tumors in only 2/18 mice with a 6 month latency period. Reinjection of cells recovered from these tumors after 1 or 2 cycles of growth in nude mice produced tumors in 2/4 and 2/3 mice with markedly decreased latent intervals of 12, 25, 25 and 25 days each. The chromosomal complement of each tumor was human, consistently pseudodiploid, and retained the Y chromosome. In both anchorage-independent and adherent cell growth assays, EGF stimulated proliferation by approximately 2-fold in both the parental P69SV40T line and the tumor sublines. The tumor sublines expressed less EGFR protein than the parental line, as assessed by Western immunoblotting and flow cytometric analysis. Immunoprecipitation revealed increased production of the 18 and 25 kDa TGF-alpha precursors parallel to decreases in detectable EGFR. The growth of both the parental P69SV40T line and the tumor sublines was inhibited by a neutralizing antibody to TGF-alpha under serum-free defined conditions. Inclusion of the TGF-alpha neutralizing antibody consistently inhibited the proliferation of the tumor sublines more than P69SV40T in both proliferation and [3H]thymidine incorporation assays. This finding suggests that the increased tumorigenicity and decreased latent interval observed among the human prostate tumor cells is partially due to activation of the TGF-alpha/EGFR autocrine network.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8077059     DOI: 10.1002/ijc.2910580517

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  29 in total

1.  Toward a high-throughput approach to quantitative proteomic analysis: expression-dependent protein identification by mass spectrometry.

Authors:  T J Griffin; D K Han; S P Gygi; B Rist; H Lee; R Aebersold; K C Parker
Journal:  J Am Soc Mass Spectrom       Date:  2001-12       Impact factor: 3.109

Review 2.  Pharmacological approaches to defining the role of chaperones in aging and prostate cancer progression.

Authors:  Sarah A Harvey; Keith O Jensen; Lynne W Elmore; Shawn E Holt
Journal:  Cell Stress Chaperones       Date:  2002-04       Impact factor: 3.667

3.  Progression to metastatic stage in a cellular model of prostate cancer is associated with methylation of the androgen receptor gene and transcriptional suppression of the insulin-like growth factor-I receptor gene.

Authors:  Hagit Schayek; Itay Bentov; Shihua Sun; Stephen R Plymate; Haim Werner
Journal:  Exp Cell Res       Date:  2010-03-23       Impact factor: 3.905

4.  Control of protein kinase C activity, phorbol ester-induced cytoskeletal remodeling, and cell survival signals by the scaffolding protein SSeCKS/GRAVIN/AKAP12.

Authors:  Li-Wu Guo; Lingqiu Gao; Julian Rothschild; Bing Su; Irwin H Gelman
Journal:  J Biol Chem       Date:  2011-09-07       Impact factor: 5.157

5.  Type-1 insulin-like growth factor receptor reexpression in the malignant phenotype of SV40-T-immortalized human prostate epithelial cells enhances apoptosis.

Authors:  S S Plymate; V L Bae; L Maddison; L S Quinn; J L Ware
Journal:  Endocrine       Date:  1997-08       Impact factor: 3.633

Review 6.  Current mouse and cell models in prostate cancer research.

Authors:  Xinyu Wu; Shiaoching Gong; Pradip Roy-Burman; Peng Lee; Zoran Culig
Journal:  Endocr Relat Cancer       Date:  2013-06-24       Impact factor: 5.678

7.  MicroRNA-17-3p is a prostate tumor suppressor in vitro and in vivo, and is decreased in high grade prostate tumors analyzed by laser capture microdissection.

Authors:  Xueping Zhang; Amy Ladd; Ema Dragoescu; William T Budd; Joy L Ware; Zendra E Zehner
Journal:  Clin Exp Metastasis       Date:  2009-09-22       Impact factor: 5.150

8.  Malignancy-associated regions of transcriptional activation: gene expression profiling identifies common chromosomal regions of a recurrent transcriptional activation in human prostate, breast, ovarian, and colon cancers.

Authors:  Gennadi V Glinsky; Anja Krones-Herzig; Anna B Glinskii
Journal:  Neoplasia       Date:  2003 May-Jun       Impact factor: 5.715

9.  Inhibition of vimentin or beta1 integrin reverts morphology of prostate tumor cells grown in laminin-rich extracellular matrix gels and reduces tumor growth in vivo.

Authors:  Xueping Zhang; Marcia V Fournier; Joy L Ware; Mina J Bissell; Adly Yacoub; Zendra E Zehner
Journal:  Mol Cancer Ther       Date:  2009-03-10       Impact factor: 6.261

10.  Beta2-microglobulin signaling blockade inhibited androgen receptor axis and caused apoptosis in human prostate cancer cells.

Authors:  Wen-Chin Huang; Jonathan J Havel; Haiyen E Zhau; Wei Ping Qian; Hui-Wen Lue; Chia-Yi Chu; Takeo Nomura; Leland W K Chung
Journal:  Clin Cancer Res       Date:  2008-09-01       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.